These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11237071)

  • 1. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker.
    ten Berge RL; Oudejans JJ; Dukers DF; Meijer JW; Ossenkoppele GJ; Meijer CJ
    Leukemia; 2001 Mar; 15(3):458-64. PubMed ID: 11237071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma.
    ten Berge RL; Dukers DF; Oudejans JJ; Pulford K; Ossenkoppele GJ; de Jong D; Miseré JF; Meijer CJ
    Blood; 1999 Apr; 93(8):2688-96. PubMed ID: 10194449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease.
    Oudejans JJ; Jiwa NM; Kummer JA; Ossenkoppele GJ; van Heerde P; Baars JW; Kluin PM; Kluin-Nelemans JC; van Diest PJ; Middeldorp JM; Meijer CJ
    Blood; 1997 Feb; 89(4):1376-82. PubMed ID: 9028961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients.
    Kagami Y; Suzuki R; Taji H; Yatabe Y; Takeuchi T; Maeda S; Kondo E; Kojima M; Motoori T; Mizoguchi Y; Okamoto M; Ohnishi K; Yamabe H; Seto M; Ogura M; Koshikawa T; Takahashi T; Kurita S; Morishima Y; Suchi T; Nakamura S
    Am J Surg Pathol; 1999 Oct; 23(10):1184-200. PubMed ID: 10524519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma.
    Asano N; Suzuki R; Matsuo K; Kagami Y; Ishida F; Tamaru JI; Jin GS; Sato Y; Shimoyama Y; Yoshino T; Morishima Y; Nakamura S
    Histopathology; 2007 May; 50(6):705-15. PubMed ID: 17493234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules.
    Foss HD; Anagnostopoulos I; Araujo I; Assaf C; Demel G; Kummer JA; Hummel M; Stein H
    Blood; 1996 Nov; 88(10):4005-11. PubMed ID: 8916967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
    Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
    Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.
    Muris JJ; Meijer CJ; Cillessen SA; Vos W; Kummer JA; Bladergroen BA; Bogman MJ; MacKenzie MA; Jiwa NM; Siegenbeek van Heukelom LH; Ossenkoppele GJ; Oudejans JJ
    Leukemia; 2004 Mar; 18(3):589-96. PubMed ID: 14712286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin.
    Krenacs L; Wellmann A; Sorbara L; Himmelmann AW; Bagdi E; Jaffe ES; Raffeld M
    Blood; 1997 Feb; 89(3):980-9. PubMed ID: 9028330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.
    ten Berge RL; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Oudejans JJ; Meijer JW; Willemze R; Hilgers J; Meijer CJ
    J Clin Pathol; 2001 Dec; 54(12):933-9. PubMed ID: 11729213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
    ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
    Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas.
    Dukers DF; ten Berge RL; Oudejans JJ; Pulford K; Hayes D; Miseré JF; Ossenkoppele GJ; Jaspars LH; Willemze R; Meijer CJ
    J Clin Pathol; 1999 Feb; 52(2):129-36. PubMed ID: 10396241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
    Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
    Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.
    Pittaluga S; Wlodarska I; Pulford K; Campo E; Morris SW; Van den Berghe H; De Wolf-Peeters C
    Am J Pathol; 1997 Aug; 151(2):343-51. PubMed ID: 9250148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.
    Suzuki R; Kagami Y; Takeuchi K; Kami M; Okamoto M; Ichinohasama R; Mori N; Kojima M; Yoshino T; Yamabe H; Shiota M; Mori S; Ogura M; Hamajima N; Seto M; Suchi T; Morishima Y; Nakamura S
    Blood; 2000 Nov; 96(9):2993-3000. PubMed ID: 11049976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
    Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
    Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization.
    de Bruin PC; Kummer JA; van der Valk P; van Heerde P; Kluin PM; Willemze R; Ossenkoppele GJ; Radaszkiewicz T; Meijer CJ
    Blood; 1994 Dec; 84(11):3785-91. PubMed ID: 7524749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
    Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
    Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance?
    Brink AA; Oudejans JJ; van den Brule AJ; Kluin PM; Horstman A; Ossenkoppele GJ; van Heerde P; Jiwa M; Meijer CJ
    Mod Pathol; 1998 Apr; 11(4):376-83. PubMed ID: 9578089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
    Bakshi NA; Finn WG; Schnitzer B; Valdez R; Ross CW
    Arch Pathol Lab Med; 2007 May; 131(5):742-7. PubMed ID: 17488159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.